Core Viewpoint - The article discusses the competitive landscape of oral GLP-1 weight loss drugs, highlighting Structure Therapeutics' aleniglipron as a strong contender following positive Phase II clinical trial results, which showed significant weight loss compared to existing treatments [4][5][6]. Group 1: Aleniglipron's Clinical Results - Structure Therapeutics announced that aleniglipron demonstrated a weight loss of 16.3% in the 180 mg dose group and 16.0% in the 240 mg dose group after 11 months of treatment [4]. - Previous data indicated that the 120 mg dose group achieved an 11.3% weight loss after 9 months [4]. - Analysts noted that aleniglipron's efficacy is competitive, even outperforming other oral GLP-1 candidates like orforglipron and oral Wegovy [6]. Group 2: Comparison with Competitors - Novo Nordisk's oral Wegovy showed a weight loss of 13.6% after 16 months in Phase III trials, while Eli Lilly's orforglipron achieved a maximum weight loss of 11.2% in its Phase III study [5]. - The FDA is expected to make a decision on orforglipron's market application by mid-April [5]. Group 3: Tolerability and Market Potential - Aleniglipron has a low discontinuation rate due to side effects, ranging from 2% to 3.4%, which is significantly lower than orforglipron's 10.3% and oral Wegovy's 16.9% [6]. - The oral GLP-1 drug market is gaining attention due to its potential to expand the weight loss drug market, as oral formulations offer greater convenience and accessibility compared to injectables [6]. Group 4: Future Developments - Structure plans to initiate Phase III clinical trials for aleniglipron this year, with the potential for the drug to become a significant player in the oral weight loss market if further efficacy and safety are confirmed [7]. - Despite a positive market reaction to the recent data, Structure's stock has declined by 22% year-to-date, indicating cautious investor sentiment regarding its future clinical and commercial prospects [7].